Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

TCT 2021 | First-line axicabtagene ciloleucel in lymphoma

Yago Nieto • 15 Feb 2021
TCT 2021
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Axicabtagene ciloleucel

Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses the use of axicabtagene ciloleucel in the front-line setting for patients with relapsed/refractory non-Hodgkin lymphoma. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Yago Nieto

High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
2:10
High-dose chemotherapy and autoSCT for R/R primary mediastinal large B-cell lymphoma
Yago Nieto • 11 Dec 2023
AFM13 with cord blood-derived NK-cell therapy in patients with refractory CD30-positive lymphomas
2:55
AFM13 with cord blood-derived NK-cell therapy in patients with refractory CD30-positive lymphomas
Yago Nieto • 11 Dec 2023
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
3:32
Phase II study of panobinostat/GemBuMel with autoSCT in high-risk or R/R multiple myeloma
Yago Nieto • 13 Feb 2023
Phase I/II study of olaparib plus vorinostat/GemBuMel with autoSCT in R/R lymphomas
2:33
Phase I/II study of olaparib plus vorinostat/GemBuMel with autoSCT in R/R lymphomas
Yago Nieto • 11 Dec 2022

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Yago Nieto • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
Yago Nieto • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
Yago Nieto • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Yago Nieto • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals